Skip to main content
Erschienen in: International Journal of Hematology 3/2016

06.06.2016 | Original Article

Elevated levels of miR-210 correlate with anemia in β-thalassemia/HbE patients

verfasst von: Panjaree Siwaponanan, Suthat Fucharoen, Pornpan Sirankapracha, Pranee Winichagoon, Tsukuru Umemura, Saovaros Svasti

Erschienen in: International Journal of Hematology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Ineffective erythropoiesis in β-thalassemia patients is caused by the premature death of red blood cell precursors due to excess α-globin chains. As a consequence, patients develop chronic anemia and hypoxia. Upregulation of miR-210, a hypoxia-induced miRNA, has been shown to regulate globin gene expression and erythroid differentiation in β-thalassemia/HbE erythroid progenitor cell culture. The present study examined whether the expression of miR-210 in circulation reflects the anemic condition in these patients. The level of miR-210 expression was directly examined from red blood cells and plasma of β-thalassemia/HbE patients. Transferrin receptor, a marker of erythropoiesis activity, was also analyzed. Increased expression of both red blood cells and plasma miR-210 as well as elevated levels of serum transferrin receptor in β-thalassemia/HbE patients were observed when compared to those of normal individuals (p < 0.05). In addition, red blood cell miR-210 level was inversely correlated with hemoglobin levels (r = −0.7054, p < 0.01) and hematocrit (r = −0.6017, p < 0.05). The higher expression of miR-210 in these patients may be the consequence of hypoxia occurring from the lower hemoglobin level. Thus, analysis of red blood cell miR-210 may be useful as a method for assessing hypoxia in β-thalassemia patients.
Literatur
1.
Zurück zum Zitat Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A. 2008;105:3333–8.CrossRefPubMedPubMedCentral Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A. 2008;105:3333–8.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Pase L, Layton JE, Kloosterman WP, Carradice D, Waterhouse PM, Lieschke GJ. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood. 2009;113:1794–804.CrossRefPubMedPubMedCentral Pase L, Layton JE, Kloosterman WP, Carradice D, Waterhouse PM, Lieschke GJ. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood. 2009;113:1794–804.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008;14:843–53.CrossRefPubMedPubMedCentral Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008;14:843–53.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Azzouzi I, Moest H, Winkler J, Fauchere JC, Gerber AP, Wollscheid B, et al. MicroRNA-96 directly inhibits gamma-globin expression in human erythropoiesis. PLoS ONE. 2011;6:e22838.CrossRefPubMedPubMedCentral Azzouzi I, Moest H, Winkler J, Fauchere JC, Gerber AP, Wollscheid B, et al. MicroRNA-96 directly inhibits gamma-globin expression in human erythropoiesis. PLoS ONE. 2011;6:e22838.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Gabbianelli M, Testa U, Morsilli O, Pelosi E, Saulle E, Petrucci E, et al. Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica. 2010;95:1253–60.CrossRefPubMedPubMedCentral Gabbianelli M, Testa U, Morsilli O, Pelosi E, Saulle E, Petrucci E, et al. Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica. 2010;95:1253–60.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kosaka N, Sugiura K, Yamamoto Y, Yoshioka Y, Miyazaki H, Komatsu N, et al. Identification of erythropoietin-induced microRNAs in haematopoietic cells during erythroid differentiation. Br J Haematol. 2008;142:293–300.CrossRefPubMed Kosaka N, Sugiura K, Yamamoto Y, Yoshioka Y, Miyazaki H, Komatsu N, et al. Identification of erythropoietin-induced microRNAs in haematopoietic cells during erythroid differentiation. Br J Haematol. 2008;142:293–300.CrossRefPubMed
7.
Zurück zum Zitat Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep. 2009;42:493–9.CrossRefPubMed Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMB Rep. 2009;42:493–9.CrossRefPubMed
10.
Zurück zum Zitat Fucharoen S, Youngchaiyud P, Wasi P. Hypoxaemia and the effect of aspirin in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12:90–3.PubMed Fucharoen S, Youngchaiyud P, Wasi P. Hypoxaemia and the effect of aspirin in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12:90–3.PubMed
11.
Zurück zum Zitat Svasti S, Masaki S, Penglong T, Abe Y, Winichagoon P, Fucharoen S, et al. Expression of microRNA-451 in normal and thalassemic erythropoiesis. Ann Hematol. 2010;89:953–8.CrossRefPubMed Svasti S, Masaki S, Penglong T, Abe Y, Winichagoon P, Fucharoen S, et al. Expression of microRNA-451 in normal and thalassemic erythropoiesis. Ann Hematol. 2010;89:953–8.CrossRefPubMed
12.
Zurück zum Zitat Sarakul O, Vattanaviboon P, Tanaka Y, Fucharoen S, Abe Y, Svasti S, et al. Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis. 2013;51:98–103.CrossRefPubMed Sarakul O, Vattanaviboon P, Tanaka Y, Fucharoen S, Abe Y, Svasti S, et al. Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis. 2013;51:98–103.CrossRefPubMed
13.
Zurück zum Zitat Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.CrossRefPubMedPubMedCentral Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2010;3:109–13.CrossRefPubMedPubMedCentral Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol. 2010;3:109–13.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull. 2013;36:48–54.CrossRefPubMed Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull. 2013;36:48–54.CrossRefPubMed
16.
Zurück zum Zitat Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, Faulhaber-Walter R, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2011;6:1540–6.CrossRefPubMed Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, Faulhaber-Walter R, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2011;6:1540–6.CrossRefPubMed
17.
18.
Zurück zum Zitat Doss JF, Corcoran DL, Jima DD, Telen MJ, Dave SS, Chi JT. A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. BMC Genom. 2015;16:952.CrossRef Doss JF, Corcoran DL, Jima DD, Telen MJ, Dave SS, Chi JT. A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. BMC Genom. 2015;16:952.CrossRef
19.
Zurück zum Zitat Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med. 2011;15:1239–53.CrossRefPubMedPubMedCentral Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med. 2011;15:1239–53.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Zaccagnini G, Maimone B, Di Stefano V, Fasanaro P, Greco S, Perfetti A, et al. Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia. Antioxid Redox Signal. 2014;21:1177–88.CrossRefPubMedPubMedCentral Zaccagnini G, Maimone B, Di Stefano V, Fasanaro P, Greco S, Perfetti A, et al. Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia. Antioxid Redox Signal. 2014;21:1177–88.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Hale A, Lee C, Annis S, Min PK, Pande R, Creager MA, et al. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta. 2014;1843:2528–42.CrossRefPubMedPubMedCentral Hale A, Lee C, Annis S, Min PK, Pande R, Creager MA, et al. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta. 2014;1843:2528–42.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35:856–67.CrossRefPubMedPubMedCentral Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009;35:856–67.CrossRefPubMedPubMedCentral
23.
24.
Zurück zum Zitat Elsayh KI, Zahran AM, El-Abaseri TB, Mohamed AO, El-Metwally TH. Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with Thalassemia in Upper Egypt. Clin Appl Thromb Hemost. 2014;20:536–45.CrossRefPubMed Elsayh KI, Zahran AM, El-Abaseri TB, Mohamed AO, El-Metwally TH. Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with Thalassemia in Upper Egypt. Clin Appl Thromb Hemost. 2014;20:536–45.CrossRefPubMed
25.
Zurück zum Zitat Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol. 2004;286:R977–88.CrossRefPubMed Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol. 2004;286:R977–88.CrossRefPubMed
26.
Zurück zum Zitat Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 2007;435:179–97.CrossRefPubMed Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 2007;435:179–97.CrossRefPubMed
27.
Zurück zum Zitat Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood. 1993;81:1067–76.PubMed Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood. 1993;81:1067–76.PubMed
28.
Zurück zum Zitat Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood. 1990;75:102–7.PubMed Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood. 1990;75:102–7.PubMed
29.
Zurück zum Zitat Paritpokee N, Wiwanitkit V, Bhokaisawan N, Boonchalermvichian C, Preechakas P. Serum erythropoietin levels in pediatric patients with beta-thalassemia/hemoglobin E. Clin Lab. 2002;48:631–4.PubMed Paritpokee N, Wiwanitkit V, Bhokaisawan N, Boonchalermvichian C, Preechakas P. Serum erythropoietin levels in pediatric patients with beta-thalassemia/hemoglobin E. Clin Lab. 2002;48:631–4.PubMed
30.
Zurück zum Zitat Sawant M. S C, Colah R, Ghosh K, Nadkarni A. Does HbF induction by hydroxycarbamide work through MIR210 in sickle cell anaemia patients? Br J Haematol. 2016;173:801–3.CrossRefPubMed Sawant M. S C, Colah R, Ghosh K, Nadkarni A. Does HbF induction by hydroxycarbamide work through MIR210 in sickle cell anaemia patients? Br J Haematol. 2016;173:801–3.CrossRefPubMed
31.
Metadaten
Titel
Elevated levels of miR-210 correlate with anemia in β-thalassemia/HbE patients
verfasst von
Panjaree Siwaponanan
Suthat Fucharoen
Pornpan Sirankapracha
Pranee Winichagoon
Tsukuru Umemura
Saovaros Svasti
Publikationsdatum
06.06.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2032-0

Weitere Artikel der Ausgabe 3/2016

International Journal of Hematology 3/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.